SIGNATOPE specializes in the development of innovative immunoassays that enable the detection and quantification of protein biomarkers across various species and specimen types, including human samples. Their technology utilizes antibodies that target short epitopes of four amino acids, which enhances the specificity and sensitivity of the assays. This approach allows for the effective measurement of challenging proteins, such as drug transporters, and facilitates the establishment of quantitative assays for different protein isoforms. The company’s assays are particularly valuable in the context of drug safety, as they can identify potential organ toxicity and adverse drug reactions.

In addition to their core immunoassay technology, SIGNATOPE offers tailored assay and antibody development services, catering to the needs of clients in the pharmaceutical and chemical industries. Their innovative analysis strategy leverages mass spectrometry to provide rapid and cost-effective identification of biomarkers associated with organ damage and drug interactions. This capability positions SIGNATOPE as a leader in the biotech field, recognized for its growth and innovation, as evidenced by its inclusion in the Deloitte Technology Fast 50 list of rapidly growing technology companies in Germany.

Germany

SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE´s immunoassays.

SIGNATOPE

Company Details